Early-stage trials indicated that British drug maker AstraZeneca's coronavirus vaccine, which it is developing with the University of Oxford, was safe and effective, according to results published Thursday in The Lancet, a top medical journal. The study of 560 healthy adults found that the vaccine produced a similar immune response in all adults, meaning it could protect older people who face a "significant risk" of developing a severe illness if they are infected with the coronavirus.
"We hope that this means our vaccine will help to protect some of the most vulnerable people in society," said Dr. Maheshi Ramasamy, a co-author of the study at the University of Oxford, "but further research will be needed before we can be sure."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Continue reading for free
We hope you're enjoying The Week's refreshingly open-minded journalism.
Subscribed to The Week? Register your account with the same email as your subscription.